Long-term clearance of inhaled UO2 particles from the pulmonary region of the rat.
This paper reports on an enriched uranium dioxide (UO2) mass clearance study undertaken with Fischer-344 rats. The UO2 had a uranium (U) isotopic composition of 0.79% 234U, 92.8% 235U, 0.34% 236U and 6.06% 238U, by mass, with an alpha-particle activity of 1.91 Bq micrograms-1. Forty-six rats were exposed to an enriched UO2 aerosol that had an activity median particle aerodynamic diameter ranging from 2.7 to 3.2 microns. The rats were killed from 1 to 720 d post-inhalation (PI). The mass of enriched UO2 present in the trachea, lung lobes, thoracic lymph nodes, kidneys, liver, spleen, gut, and the remainder of the carcass was assessed at death. At 720 d after exposure, 82% of the total body burden of enriched UO2 was in the lung, with a further 10% in the thoracic lymph nodes. This represented 17% and 2% of the original (5 d PI) lung burden. The mass clearance of enriched UO2 from the lung was fitted to a single exponential function, normalized to 100% at 5 d PI. The rate constant (k) was 2.8 X 10(-3) d-1, giving a clearance half-time of 247 d. Although statistical comparisons with the majority of published data were not possible, it appeared that both enriched UO2 and natural UO2 particles cleared at rates that were broadly similar, with a t1/2 in the rat lung of 150 to 300 d over the 5- to 720-d PI period. As a consequence of the 234U component in the inhaled UO2 particles, the rats killed at 720 d PI received a total mean accumulated alpha-particle dose averaged over the whole lung of 5.7 Gy. Histologic investigations of the rat lungs found that widespread lung disease was only observed in animals killed at 720 d PI.
Morris
K J
KJ
M.R.C. Radiobiology Unit, Chilton, Oxon, United Kingdom.
Khanna
P
P
Batchelor
A L
AL
D000280:Administration, Inhalation; D000336:Aerosols; D000818:Animals; D008168:Lung / Q000378:metabolism*; D008297:Male; D051381:Rats; D011916:Rats, Inbred F344; D013997:Time Factors; D014018:Tissue Distribution; D014501:Uranium / Q000008:administration & dosage / Q000493:pharmacokinetics*; D017974:Uranium Compounds
D000336:Aerosols; D017974:Uranium Compounds; D014501:Uranium; C012597:uranium dioxide